MiNK Therapeutics (NASDAQ: INKT) reported a narrowed net loss of $3.1 million for the second quarter of 2026, compared to a loss of $4.2 million in the same period last year. The biotechnology company advanced its lead candidate, Agent 797, into a randomized phase 2 study for acute lung injury and acute respiratory distress syndrome (ARDS), while initiating its first international paid named patient access program in Brazil.

The company ended the quarter with $8.8 million in cash and cash equivalents, down from $9.5 million at the end of March 2026 but significantly higher than the $3.4 million held at year-end 2025. Operating cash used was $2.1 million, up from $1.6 million a year ago, reflecting targeted investments in launching the randomized phase 2 trial and activating clinical sites in Ukraine and the United States.

Clinical Progress and Strategic Initiatives

MiNK moved Agent 797 into study C1302, a randomized phase 2 trial evaluating the cell therapy plus standard of care versus placebo plus standard of care in adult patients with acute lung injury. The study opened at First Lviv Territorial Medical Union in Ukraine, with the first patient dosed within days of Ministry of Health authorization.

Initial observations from the first two treated patients showed improved oxygenation, resolution of ARDS, and liberation from vasopressor support by day 28. No major serious adverse events were attributed to Agent 797 in these early cases. Management noted that these patients had multidrug-resistant infections, a common complication in conflict zones.

In parallel, MiNK launched a paid named patient access program in Brazil in collaboration with Orphan Drug Consultants. This initiative allows treating physicians to request Agent 797 for individual patients with serious unmet needs subject to regulatory authorization. The program generates revenue on a per-patient basis and establishes international logistics infrastructure for delivering off-the-shelf cell therapy across borders.

Financial Performance

For the first six months of 2026, MiNK reported a net loss of $5.9 million, or $1.20 per share, compared to a loss of $7 million, or $1.76 per share, in the same period of 2025. The quarterly loss per share was $0.62, down from $1.06 in Q2 2025.

Management emphasized financial discipline, noting that headcount and fixed infrastructure remain lean. The company continues to prioritize non-dilutive funding, with its graft-versus-host disease trial at the University of Wisconsin and pediatric PRM program externally funded. The paid named patient access program also provides resource support for ongoing clinical trials.

What the Numbers Show

The narrowing net loss occurred alongside an increase in operating cash burn, indicating that cost reductions or efficiency gains outpaced the additional spending required to launch the phase 2 study. With cash reserves at $8.8 million and a quarterly burn rate of approximately $2.1 million, the company maintains runway for roughly four quarters of current operations without additional funding, assuming no significant changes in spend or revenue from the named patient program.

MiNK Therapeutics Inc. (NASDAQ: INKT) presented early clinical observations from its ongoing Phase 2 trial of agenT-797 at the 2026 Military Health System Research Symposium on August 6, 2026. The data revealed that initial patients treated with the off-the-shelf allogeneic invariant natural killer T-cell (iNKT) therapy for severe hypoxemic pneumonia were alive and afebrile at the Day 28 endpoint. These patients demonstrated substantially improved hemodynamics, mental status, and oxygenation, alongside successful removal from ventilator and vasopressor support, marking a critical early success for a therapy designed to restore barrier immunity in life-threatening lung injury.

The presentation, delivered by Dr. Terese Hammond, M.D., Head of Inflammatory and Pulmonary Diseases at MiNK Therapeutics, detailed biological changes associated with immune recovery and tissue repair. Analysis of blood and lung fluid samples indicated control of baseline infections, reduced inflammatory markers, and increased production of cytokines linked to pulmonary tissue healing. No major serious adverse events attributed to agenT-797 were reported among these first treated patients, who entered the study with severe respiratory failure and complex infections.

Trial Design and Operational Context

The C-1300-02 trial is a randomized Phase 2 study evaluating agenT-797 plus standard of care compared with placebo plus standard of care. The study targets adults with acute lung injury and critical illness, including moderate to severe acute hypoxemic respiratory failure meeting Global ARDS criteria. The trial received authorization from the Ukraine Ministry of Health and is supported by an active U.S. Investigational New Drug (IND) application.

Enrollment is currently ongoing at the First Lviv Territorial Medical Union in Lviv, Ukraine, with expansion into U.S. centers actively underway. MiNK Therapeutics emphasized the operational advantages of its off-the-shelf approach, which allows for immediate dosing from inventory without the need for patient-specific manufacturing, HLA matching, or lymphodepletion. This capability enabled the company to dose its first patient within days of regulatory approval.

Strategic Implications

Jennifer Buell, PhD, President and Chief Executive Officer of MiNK Therapeutics, stated that the rapid pace of activation and dosing underscores the importance of therapies that can reach patients in contested and resource-limited environments. The company noted that severe lung injury carries high mortality and lacks approved therapies proven to reduce it, particularly in conflict settings where multidrug-resistant infections can render traditional antibiotics ineffective.

Dr. Hammond added that the biological changes observed are consistent with earlier findings presented at the American Society of Gene & Cell Therapy (ASGCT) and the American Thoracic Society (ATS). The company anticipates additional data from the ongoing trial in early 2027, as enrollment continues across international sites. The presentation was part of the Cellular Therapies for Trauma session at the symposium, held at the Gaylord Palms Resort and Convention Center in Kissimmee, Florida.